This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy. This Plain Language Summary of Publication article from Future Oncology describes the result of a phase 3 study called TOPAZ-1.  The study looked at treatment durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC).

Visit Future Medicine using the link to read the article.

The original article on which this summary is based on is called ‘Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer’ and was published in NEJM Evidence.

Visit NEJM Medicine using the link to read the article.